Verteporfin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Verteporfin. Educational only — not medical advice.
Labeled uses
VISUDYNE® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV.
Source: FDA labeling via NIH DailyMed (set 2f0a34ce…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.